|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease显示文摘Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond well to anti-tumor necrosis factor (TNF) therapy. However, serious side effects do occur, necessitating careful monitoring of therapy. Potential side effects of anti-TNF therapy include opportunistic infections, which show a higher incidence when concomitant immunosuppression is used. Furthermore, antibody formation against anti-TNF is associated with decreased efficacy and an increased frequency of infusion reactions. The hypothesis of a slightly increased risk of lymphomas in IBD patients treated with anti TNF-therapy is debatable, since most studies lack the specific design to properly address this issue. Alarmingly, the occurrence of hepatosplenic T-cell lymphomas coincides with combined immunosuppressive therapy. Despite the potential serious side effects, anti-TNF therapy is an effective and relatively safe treatment option for refractory IBD. Future research is needed to answer important questions, such as the long-term risk of malignancies, safety during pregnancy, when to discontinue and when to switch anti-TNF therapy, as well as to determine the balance between therapeutic and toxic effects. | Frank Hoentjen Ad A van Bodegraven | 2009 | World Journal of Gastroenterology2009，15，17： | 19 |
| 2 | Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review显示文摘AIM To critically assess the available literature regarding the efficacy of thioguanine treatment in inflammatory bowel disease(IBD) patients, irrespective of the(hepato-) toxicity profile.METHODS A systematic literature search of the MEDLINE database using Pub Med was performed using the keywords 'thioguanine', '6-TG', 'thioguanine', 'inflammatory bowel disease', 'IBD', 'Crohn's disease', 'Ulcerative colitis' and 'effectiveness' in order to identify relevant articles published in English starting from 2000. Reference lists of the included articles were crosschecked for missing articles. Reviewed manuscripts concerning the effectiveness of thioguanine treatment in IBD were reviewed by the authors and the data were extracted. Data were subsequently analyzed with descriptive statistics. Due to the lack of standardized outcomes, a formal meta-analysis was not performed.RESULTS A total of 11 applicable studies were found that involved the effectiveness of thioguanine therapy in IBD. Eight studies were conducted in a prospectivemanner, in the remaining three studies, data was collected retrospectively. In total, 353 IBD-patients(225 patients with Crohn's disease, 119 with ulcerative colitis and nine with unclassified IBD) with prior azathioprine/mercaptopurine resistance and/or intolerance(n = 321) or de novo thioguanine administration(n = 32) were included for analysis, of which 228(65%) had clinical improvement on thioguanine therapy, based on standard IBD questionnaires, biochemical parameters or global physician assessments. Short-term results were based on 268 treatment years(median follow-up 9 mo, range 3-22 mo) with a median daily dose of 20 mg(range 10-80 mg). Discontinuation, mostly due to adverse events, was reported in 72 patients(20%). CONCLUSION The efficacy of thioguanine therapy in IBD patients intolerant to conventional thiopurine therapy is observed in 65%, with short term adverse events in 20% of patients. | Berrie Meijer Chris JJ Mulder Godefridus J Peters Adriaan A van Bodegraven Nanne KH de Boer | 2016 | World Journal of Gastroenterology2016，22，40： | 5 |
| 3 | Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population显示文摘AIM: To describe the characteristics of Dutch patients with chronic inflammatory bowel disease (IBD) first diagnosed above 60 years of age-a disease also known as old-age colitis (OAC) and to highlight a condition that has a similar appearance to IBD, namely segmen- tal colitis associated with diverticular disease (SCAD). METHODS: A retrospective longitudinal survey of patient demographic and clinical characteristics, disease characteristics, diagnostic methods, management and course of disease was performed. The median follow-up period was 10 years. RESULTS: Of a total of 1100 IBD patients attending the Department of Gastroenterology, 59 (5%) [median age 82 years (range 64-101); 25 male (42%)] were identified. These patients were diagnosed with ulcerative colitis (n = 37, 61%), Crohn’s disease (n = 14, 24%), and indeterminate colitis (n = 8, 15%). Remission was induced in 40 (68%) patients within a median interval of 6 mo (range 1-21) and immunosuppressive therapy was well tolerated. Histological evaluation based on many biopsy samples and the course of the disease led to other diagnosis, namely SCAD instead of IBD in five (8%) patients. CONCLUSION: OAC is not an infrequent problem for the gastroenterologist, and should be considered in the evaluation of older patients with clinical featuressuggestive of IBD. Extra awareness and extensive biopsy sampling are required in order to avoid an erroneous diagnosis purely based on histological mimicry of changes seen in SCAD, when diagnosing IBD in the presence of diverticulosis coli. | Muhammed Hadithi Marcel Cazemier Gerrit A Meijer Elisabeth Bloemena Richel J Felt-Bersma Chris J Mulder Stephan GM Meuwissen Amado Salvador Pea Adriaan A van Bodegraven | 2008 | World Journal of Gastroenterology2008，14，20： | 3 |
| 4 | Indications for 5-aminosalicylate in inflammatory bowel disease:Is the body of evidence complete?显示文摘Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and con- comitant drug pharmacokinetics, or in chemoprevention against inflammatory bowel disease (IBD)-related co- lonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dos- age to improve compliance. Therefore, due to its supe- rior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, pae- diatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use. | Ad A van Bodegraven Chris JJ Mulder | 2006 | World Journal of Gastroenterology2006，12，38： | 2 |
| 5 | Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts显示文摘 | B.Jharap M.L.Seinen N.K.H.de Boer J.R.van Ginkel R.K.Linskens J.C.Kneppelhout C.J.J.Mulder A.A.van Bodegraven | 2010 | Inflamm Bowel Dis2010，，9： | 2 |
| 6 | Long‐term follow‐up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease显示文摘 | T. G. J. Meij B. Jharap C. M. F. Kneepkens A. A. Bodegraven N. K. H. Boer | 2013 | Aliment Pharmacol Ther2013，，1： | 2 |
| 7 | Adalimumab for Crohn’s disease: Long-term sustained benefit in a population-based cohort of 438 patients显示文摘 | Charlotte P. Peters Emma J. Eshuis Florien M. Toxopeüs Merel E. Hellemons Jeroen M. Jansen Geert R.A.M. D’Haens Paul Fockens Pieter C.F. Stokkers Hans A.R.E. Tuynman Adriaan A. van Bodegraven Cyriel Y. Ponsioen | 2014 | Journal of Crohn’s and Colitis2014，，： | 2 |
| 8 | Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD显示文摘瞄准:调查在粘膜 S 的 ASCA 和存在之间的关联。在 CD, ulcerative (UC ) 病人和控制的一张人口的啤酒 DNA。方法:S。cerevisiae 特定的教材和一根荧光灯的探针为 5' exonuclease 实时 PCR (TaqMan ) 试金被设计,它是用为在实时的 PCR 产品的察觉的一根荧光灯标签的探针的一个同质的系统。我们在一组 76 煽动性的肠疾病(IBD ) 与 ASCA 调查结果分析了 PCR 结果的关系病人(31 CD, 45 UC ) 并且 22 健康控制(HC ) 。结果:ASCA (IgA 或 IgG ) 在 19 是积极的(61%) 有 CD 的病人, 12 (27%) 与 HC 的 UC 和没有。PCR 扩大在 10 从最后的结果被禁止并且排除(22%) UC 病人, 7 (22%) CD 病人,并且 6 (30%) HC。在里面仅仅, 15 粘膜取样, S。啤酒 DNA 被实时 PCR 检测,包括 7 (29%) 在 CD, 7 (19%) 在 UC, 1 (6%) 在 HC。在 4 CD 并且在 4 个 UC 病人, ASCA 和粘膜 S。啤酒是积极的。粘膜 S。啤酒在 3 UC,和 3 个 CD 病人在有否定 ASCA IgA 和 IgG 的联合是在场的。结论:自从 S 的存在,我们结束那。在结肠的粘膜活体检视标本的啤酒是很稀罕的, ASCA 是不大可能的被连续暴露向 S 解释。在粘膜的啤酒。因此, ASCA 形成必须在生命更早发生,层次在免疫学的此后仍然保持相对稳定易受影响的人。 | RC Mallant-Hent M Mooij BME von Blomberg RK Linskens AA van Bodegraven PHM Savelkoul | 2006 | World Journal of Gastroenterology2006，12，2： | 2 |
| 9 | Predictive value of inflammatory an d coagulation parameters in the course of severe ulcerative colitis显示文摘 | Linskens RK van Bodegraven AA Schoorl M | 2001 | Dig Dis Sci2001，46，3： | 1 |
| 10 | Diagnosis andtreatment of ( disease - related ) in - hospital malnutrition : the performance of medical and nursing staff显示文摘 | Bavelaar JW Otter CD van Bodegraven AA | 2008 | Clinical Nutrition2008，27，3： | 1 |
| 11 | Laparo- scopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized muhicenter trial 显示文摘 | Eshuis EJ Bemelman WA van Bodegraven AA | 2008 | BMC Surg2008，8，1： | 1 |
| 12 | Gallbladder contents and fasting gallbladder volumes during and after pregnancy 显示文摘 | Van Bodegraven AA Bohmer C J Manoliu RA | 1998 | Scand J Gastroenterol1998，33，9： | 1 |
| 13 | Guidelines for treatment with infliximab for Crohn's disease显示文摘 | Hommes DW Oldenburg B Van Bodegraven AA | | 0，，02： | 1 |
| 14 | A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis显示文摘 | BORM M E VAN BODEGRAVEN A A MULDER C J | 2005 | Int J Immuno- genet2005，32，： | 1 |
| 15 | Hemostatie imbalance in active and quiescent ulcerative colitis显示文摘 | Van Bodegraven AA Schoorl M Baak JP | 2001 | Am J Gastroenterol2001，96，4： | 1 |
| 16 | Allopurinol Enhances the Activity of Hypoxanthine-Guanine Phosphoribosyltransferase in Inflammatory Bowel Disease Patients During Low-Dose Thiopurine Therapy: Preliminary Data of an Ongoing Series显示文摘 | MargienL. Seinen NanneK. H. de Boer Kees Smid DirkP. van Asseldonk Gerd Bouma AdriaanA. van Bodegraven GodefridusJ. Peters | 2011 | Nucleosides Nucleotides and Nucleic Acids2011，，12： | 1 |
| 17 | Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD 显示文摘 | de Boer NK van Bodegraven AA Jharap B | 2007 | Nat Clin Pract Gastroenterol Hepatol2007，4，12： | 1 |
| 18 | Probiotics ( VSL#3 ) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study显示文摘 | Karimi O Pena AS van Bodegraven AA | 2005 | Drugs Today (Barc)2005，41，： | 1 |
| 19 | Fructo-oligosaccharides and fibre in enteral nutrition has a beneficial influence on microbiota and gastrointestinalquality of life显示文摘 | Wierdsma NJ van Bodegraven AA Uitdehaag BM | 2009 | Scand J Gastroenterol2009，44，7： | 1 |
| 20 | Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 ( a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn' s disease显示文摘 | van der Woude C J Stokkers P van Bodegraven AA | 2010 | Intlamm Bowel Dis2010，16，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员